The 2nd International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes

Last Modified: February 10, 2003

Share article

Conference Dates: October 16-18, 2003
Conference Location: New York, NY

Sponsoring Group: Imedex, Inc.

Conference Web Page URL:

Topics Covered:


  • Angiogenesis and vascular growth factors in myeloproliferative and myelodysplastic disorders

Session 1: Myelodysplasia

  • Medical and alternative therapies for the myelodysplastic disorders
  • Treatment related myelodysplastic syndromes
  • Update on marrow transplantation

Session 2: Myelofibrosis

  • A mouse model of myelofibrosis
  • Natural history and staging
  • Cellular and molecular basis of stem cell dysregulation in idiopathic myelofibrosis
  • Morphologic aspects of marrow biopsies in the myeloproliferative diseases
  • Allogeneic transplantation in idiopathic myelofibrosis
  • New therapeutic approaches for myelofibrosis

Session 3: New diagnostic markers in polycythemia vera

  • The polycythemia rubra vera 1 gene: Current update
  • The mpl receptor in polycythemia vera
  • Cytogenetics of polycythemia vera
  • Congenital erythrocytosis
  • Results of the ECLAP study
  • Is imatinib effective in polycythemia vera?

Session 4: Essential thrombocytosis and related disorders

  • Clonality studies in essential thrombocytosis
  • Mechanism of action of the thrombopoietin receptor
  • GATA mutations, as cause of megakaryocytic leukemia
  • Hereditary thrombocytosis
  • Hypereosinophilic syndromes
  • Imatinib and other forms of treatment in systemic mast cell disease

Session 5: Chronic myeloid leukemia

  • Stem cell biology and resistance to imatinib
  • Treatment results with imatinib
  • Update on autologous transplantation in chronic myelogenous leukemia
  • Treatment pathways

Conference Objectives: After successfully completing this program, participants should be able to: Discuss the role of angiogenetic and vascular growth factors in myelodysplasia and the various myeloproliferative disorders, Provide an overview of the current medical and alternative therapies for the myelodysplastic disorders, Recommend the most appropriate management strategies for myelofibrosis and chronic myeloid leukemia, Discuss the merits of new genetic markers for the diagnosis of polycythemia vera

Who Should Attend: This educational program is intended for physicians and other health care providers who are involved in and/or interested in myelodysplasia or myeloproliferative disorders. No specific knowledge or skills other than a basic training or familiarity with the practice of hematology is required for successful participation in this program.

Registration Information:, tel: 770-751-7332, fax: 770-751-7334,

Conference Fees: Physicians, Discounted $249 if received at Imedex on or before Thursday, July 31, 2003, Regular $399 if received at Imedex on or before Thursday, October 2, 2003, On-Site $499 if received at Imedex after Thursday, October 2, 2003. Nurses, Fellows or Residents, Discounted $199 if received at Imedex on or before Thursday, July 31, 2003, Regular $299, if received at Imedex on or before Thursday, October 2, 2003, On-Site $399 if received at Imedex after Thursday, October 2, 2003.

Continuing Education: Yes

Miscellany: Call for Abstracts: Participants interested in presenting data should submit abstracts online at by August 15, 2003. CME: 15.25 hours, category 1. Conference chairman: Richard T. Silver, MD,, Cornell University Medical College

Survival Studied in Myeloma and Myelodysplastic Syndrome

Mar 1, 2015 - Overall survival for multiple myeloma patients has increased substantially in recent decades for patients aged 65 years or younger, while prognosis for survival in patients with myelodysplastic syndromes can be determined by methylation in key genes, according to a pair of studies published online Dec. 28 in the Journal of Clinical Oncology.

I Wish You Knew

How cancer patients have changed my life

View More

Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.

OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More